Dr. David Mankoff discusses meta-Iodobenzylguanidine (MIBG) therapy, which is a highly targeted therapy for treatment of pheochromocytomas and paragangliomas, at the 2012 Focus on Neuroendocrine Tumors Conference.
Published
May 7, 2013
Created by
Dr. David Mankoff discusses meta-Iodobenzylguanidine (MIBG) therapy, which is a highly targeted therapy for treatment of pheochromocytomas and paragangliomas, at the 2012 Focus on Neuroendocrine Tumors Conference.
Published
May 7, 2013
Created by
BROADCASTMED